NCT00658086 - Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

June 30, 2009

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG

ALN-RSV01

administered by nebulization once daily for 3 days

DRUG

normal saline

administered by nebulization once daily for 3 days

Trial Locations (13)

Clinical Site, Nashville

Clinical Site, Cleveland

Clinical Site, Minneapolis

Clinical Site, Denver

Clinical Site, San Diego

Clinical Site, San Francisco

Clinical Site, Gainesville

Clinical Site, Atlanta

Clinical Site, Chicago

Clinical Site, Boston

Clinical Site, Sydney

Clinical Site, Brisbane

Clinical Site, Perth